BridgeBio shares positive data from gene therapy study for Canavan Disease:
- Continued, progressive improvement in motor function and achievement of motor milestones at 12-months post-treatment represents an important and statistically significant change, in contrast to the disease course observed in BridgeBio’s ongoing CANinform natural history comparator study
- Significant and sustained reductions in N-acetylaspartate (NAA) levels in urine, cerebrospinal fluid (CSF), and brain in all participants who received low dose; encouraging trends of further reduction in urine NAA in participants who received high dose BBP-812
- If approved, BridgeBio’s gene therapy for Canavan disease could be the first therapeutic option for children born with this fatal neurodevelopmental disorder
To read full press release: BridgeBio press release